Cirrhosis, Portal Hypertension, esophagus-gastric fundus varicose, massive hemorrhage of gastrointestinal tract
Conditions
Interventions
Group A:TIPSS
Group B:patients who are randomly allocated to pharmacological therapy, endoscope therapy, surgical shunt, surgical disconnection.
Sponsors
Sun Yat-Sen University
Eligibility
Sex/Gender
Male
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: stage of cirrhosis decompesation, hypersplenia, gastric and esophageal medium and serious variceal bleeding, with or without upper gastrointestinal hemorrhage, liver function Child Pugh class A-C. Imaging evidences on preoperative ultrasound, CT, MR are routinely used to appraise the presence of that diameter of portal trunk is over 0.8 cm, splenomeglia, hepatic lobes disproportion, node hyperplastic nodule, malignant lesion<=3cm, without portal vein thrombosis using for portal vein. cirrhosis with portal hypertension by pathology and adequate clinical laboratory. Predict survival is over half one year, no gravidity, patients who are suit to operation, endoscope, interventional treatment. writing informed consent of each subject.
Exclusion criteria
Exclusion criteria: polycystic liver disease, cavernous transformation of portal vein, portal vein cancer thrombin, hepatic precoma, inability or disagree to sign informed consent; pregnancy or women of childbearing potential not taking contraception; obvious mental anomaly, center nervous system abnormalities or history of attack; ECG abnormal or obvious heart disease in clinically as congestive heart failure, symptomatic coronary heart disease, arrhythmia, myocardial ischemia occurring within last 12 months. Malignant tumor occurring on any other locations within last 5 years; brain, lung, bone metastasis or terminal; patients who are receiving other clinical trial or unsuitable of clinical trail due to other causes by researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of control bleeding, the incidence of rebleeding; | — |
Secondary
| Measure | Time frame |
|---|---|
| quality of life;Economic index;Technical success rate;Liver function;Complication; | — |
Countries
China
Contacts
Public ContactYang Janyong
Outcome results
None listed